Meanwhile, with the EMA now formally starting its review of momelotinib, GSK could be in a position to get approval for the drug in late 2023/early 2024 in the EU, a few months after the FDA is ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best undervalued UK stocks to buy right now. The global markets entered 2025 in the hope that the ...

The global markets entered 2025 in the hope that the bullish run of the fourth quarter will continue in the first quarter of 2025. However, the uncertainty due to the tariffs led to the reversal ...

Supported by Swim Across America, GlaxoSmithKline, Stand Up to Cancer, Haystack Oncology, the Simon and Eve Colin Foundation, the Dalton Foundation, and grants from the National Institutes of ...

The global markets entered 2025 in the hope that the bullish run of the fourth quarter will continue in the first quarter of 2025. However, the uncertainty due to the tariffs led to the reversal of ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Save the Children and GSK have partnered together in the U.S since 2015, providing immediate emergency relief to children and families when disaster strikes and working to build safer and more ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2916. The stock has experienced fluctuations tod ...